Significantly higher levels of GFAP were found in CA1 (p < 0.05, n = 4), Cx (p < 0.01, n = 4) and Ent-Cx (p < 0.01, n = 4) of untreated 3xTg-AD mice than in CA1 of the control WT subjects (Fig 3), but no significant differences in the GFAP expression levels were found between bexarotene-treated 3xTg-AD mice and untreated 3xTg-AD mice in DG, CA3 (p < 0.01, n = 4), CA1 (p < 0.001, n = 4) and Cx and Ent-Cx (p < 0.001, n = 4) (Fig 3B). Here, GFAP is linked to Alzheimer disease.